🔥 Black Friday Sale: Save 30% or more on all Examine products
Learn more
»
| Effect | Decrease |
| Trial Design | Meta analysis |
| Trial Length | n/a |
| Number of Subjects | 31 |
| Sex | n/a |
When assessing all trials in persons on maintenance dialysis using supplementation of L-carnitine (any form) for a duration longer than two weeks, it was confirmed that there was a reduction in LDL cholesterol (not deemed clinically significant but reaching a mean reduction of −5.82mg/dL) and a reduction in C-reactive protein (clinically significant, a reduction of −3.65mg/L) although no other biomarker including those relating to erythropoietin dosage and hematocrit were affected.
No adverse effects of L-carnitine supplementation were reported in any trial.
